AAPL   322.21 (+1.56%)
MSFT   182.72 (+0.50%)
FB   226.49 (-1.16%)
GOOGL   1,430.53 (+0.72%)
NVDA   344.46 (+1.01%)
BABA   201.03 (-0.07%)
GE   6.86 (-5.90%)
TSLA   812.05 (-1.00%)
AMD   52.47 (-0.51%)
T   31.33 (-1.63%)
F   5.93 (-1.82%)
DIS   117.13 (-3.62%)
BAC   25.23 (-2.89%)
BA   151.72 (+1.47%)
AAPL   322.21 (+1.56%)
MSFT   182.72 (+0.50%)
FB   226.49 (-1.16%)
GOOGL   1,430.53 (+0.72%)
NVDA   344.46 (+1.01%)
BABA   201.03 (-0.07%)
GE   6.86 (-5.90%)
TSLA   812.05 (-1.00%)
AMD   52.47 (-0.51%)
T   31.33 (-1.63%)
F   5.93 (-1.82%)
DIS   117.13 (-3.62%)
BAC   25.23 (-2.89%)
BA   151.72 (+1.47%)
AAPL   322.21 (+1.56%)
MSFT   182.72 (+0.50%)
FB   226.49 (-1.16%)
GOOGL   1,430.53 (+0.72%)
NVDA   344.46 (+1.01%)
BABA   201.03 (-0.07%)
GE   6.86 (-5.90%)
TSLA   812.05 (-1.00%)
AMD   52.47 (-0.51%)
T   31.33 (-1.63%)
F   5.93 (-1.82%)
DIS   117.13 (-3.62%)
BAC   25.23 (-2.89%)
BA   151.72 (+1.47%)
AAPL   322.21 (+1.56%)
MSFT   182.72 (+0.50%)
FB   226.49 (-1.16%)
GOOGL   1,430.53 (+0.72%)
NVDA   344.46 (+1.01%)
BABA   201.03 (-0.07%)
GE   6.86 (-5.90%)
TSLA   812.05 (-1.00%)
AMD   52.47 (-0.51%)
T   31.33 (-1.63%)
F   5.93 (-1.82%)
DIS   117.13 (-3.62%)
BAC   25.23 (-2.89%)
BA   151.72 (+1.47%)
Log in

NASDAQ:ETTXEntasis Therapeutics Stock Price, Forecast & News

$2.77
+0.19 (+7.36 %)
(As of 05/28/2020 03:22 PM ET)
Add
Compare
Today's Range
$2.57
Now: $2.77
$2.79
50-Day Range
$2.32
MA: $2.65
$2.95
52-Week Range
$1.75
Now: $2.77
$9.25
Volume51,579 shs
Average Volume21,084 shs
Market Capitalization$40.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. Entasis Therapeutics Holdings was founded in March 2018 and is headquartered in Waltham, MA.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ETTX
CUSIPN/A
CIKN/A
Phone781-810-0120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7 million
Book Value$1.90 per share

Profitability

Net Income$-43,850,000.00

Miscellaneous

EmployeesN/A
Market Cap$40.47 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive ETTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ETTX and its competitors with MarketBeat's FREE daily newsletter.

Entasis Therapeutics (NASDAQ:ETTX) Frequently Asked Questions

How has Entasis Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Entasis Therapeutics' stock was trading at $4.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ETTX stock has decreased by 32.9% and is now trading at $2.7699. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Entasis Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entasis Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Entasis Therapeutics.

When is Entasis Therapeutics' next earnings date?

Entasis Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Entasis Therapeutics.

How were Entasis Therapeutics' earnings last quarter?

Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) issued its quarterly earnings results on Thursday, May, 7th. The company reported ($1.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.00) by $0.15. View Entasis Therapeutics' earnings history.

What price target have analysts set for ETTX?

5 analysts have issued 12 month price targets for Entasis Therapeutics' stock. Their forecasts range from $5.00 to $14.00. On average, they anticipate Entasis Therapeutics' stock price to reach $9.50 in the next year. This suggests a possible upside of 243.0% from the stock's current price. View analysts' price targets for Entasis Therapeutics.

Has Entasis Therapeutics been receiving favorable news coverage?

News articles about ETTX stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Entasis Therapeutics earned a coverage optimism score of -3.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutEntasis Therapeutics.

Are investors shorting Entasis Therapeutics?

Entasis Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 5,700 shares, a decrease of 24.0% from the April 30th total of 7,500 shares. Based on an average daily trading volume, of 27,100 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.2% of the company's stock are sold short. View Entasis Therapeutics' Current Options Chain.

Who are some of Entasis Therapeutics' key competitors?

What other stocks do shareholders of Entasis Therapeutics own?

Who are Entasis Therapeutics' key executives?

Entasis Therapeutics' management team includes the following people:
  • Manoussos Perros, President, Chief Executive Officer & Director
  • Mike Gutch, Chief Financial Officer & Chief Business Officer
  • Ruben Tommasi, Chief Scientific Officer
  • Robin Isaacs, Chief Medical Officer
  • John Mueller, Chief Development Officer

When did Entasis Therapeutics IPO?

(ETTX) raised $75 million in an initial public offering (IPO) on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.

What is Entasis Therapeutics' stock symbol?

Entasis Therapeutics trades on the NASDAQ under the ticker symbol "ETTX."

Who are Entasis Therapeutics' major shareholders?

Entasis Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Frazier Management LLC (7.18%). Company insiders that own Entasis Therapeutics stock include Group Holdings (Sbs) Advis Tpg, Holdings A/S Novo and Nicholas Galakatos. View institutional ownership trends for Entasis Therapeutics.

Which institutional investors are selling Entasis Therapeutics stock?

ETTX stock was sold by a variety of institutional investors in the last quarter, including Frazier Management LLC. View insider buying and selling activity for Entasis Therapeutics.

How do I buy shares of Entasis Therapeutics?

Shares of ETTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Entasis Therapeutics' stock price today?

One share of ETTX stock can currently be purchased for approximately $2.77.

How big of a company is Entasis Therapeutics?

Entasis Therapeutics has a market capitalization of $40.47 million and generates $7 million in revenue each year. The company earns $-43,850,000.00 in net income (profit) each year or ($3.33) on an earnings per share basis.

What is Entasis Therapeutics' official website?

The official website for Entasis Therapeutics is www.entasistx.com.

How can I contact Entasis Therapeutics?

Entasis Therapeutics' mailing address is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. The company can be reached via phone at 781-810-0120 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.